New drug may shield transplanted kidneys from silent attack
NCT ID NCT07274462
First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This study tests whether daratumumab can reduce microvascular inflammation in kidney transplant recipients. Twenty adults with signs of inflammation in their transplant biopsy will either receive the drug or standard monitoring. The goal is to see if the drug improves kidney health and function over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROVASCULAR INFLAMMATION - MVI IN KINDEY TRANSPLANT RECIPIENTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Transplant-nephrology department
Martin, 036 01, Slovakia
Conditions
Explore the condition pages connected to this study.